Hinge Health, Inc. SEC Filings

HNGE shareholders filed a Form 144 indicating an intent to sell 2,614 Class A shares through Merrill Lynch on the NYSE. The planned sale has an aggregate market value of 130,490.88, with Class A shares outstanding reported at 37,919,155. These shares were originally acquired from the issuer in a private placement on 02/04/2020 and paid for in cash on the same date.

Over the past three months, affiliated holders have already sold several large Class A blocks. Bessemer Venture Partners X LP reported sales including 373,955 shares on 11/18/2025 for gross proceeds of 14,976,898, 103,160 shares on 11/26/2025 for 4,979,533.2, and 23,176 shares on 11/28/2025 for 1,162,403.87. Bessemer Venture Partners X Institutional LP reported sales including 351,045 shares on 11/18/2025 for 14,059,352, 96,840 shares on 11/26/2025 for 4,674,466.8, and 21,757 shares on 11/28/2025 for 1,091,233.21.

Insight Venture Partners affiliates, identified as a director and 10% owner of Hinge Health, Inc. (HNGE), reported on Form 4 that on December 1, 2025 they converted multiple blocks of Class B Common Stock into Class A Common Stock and then sold those Class A shares.

The reporting persons converted and sold 826,216, 19,659, 677,508 and 131,057 shares of Class B/Class A stock, respectively, through affiliated Insight investment funds, with each corresponding Class A position shown as reduced to zero following the sales at a reported price of $47.76 per share.

Footnotes describe that each share of Class B Common Stock was convertible into one share of Class A Common Stock and outline Insight’s fund and holding-company structure, noting that various Insight entities and managers may be deemed to share voting and dispositive power over these Hinge Health shares while generally disclaiming beneficial ownership beyond their pecuniary interests.

HNGE filed a notice under Rule 144 for a proposed sale of restricted or control securities. The filing covers the planned sale of 19,659 shares of Class A stock through broker Merrill Lynch, with an aggregate market value of 961,521.69. These shares are part of a larger base of 37,919,155 shares outstanding and are expected to be sold on the NYSE on or about 12/01/2025. The seller originally acquired the 19,659 Class A shares from the issuer in a private placement on 07/03/2018, paying cash at that time.

HNGE has a shareholder planning to sell 131,057 Class A shares through Merrill Lynch on the NYSE, with an aggregate market value of $6,409,997.87. The filing notes that 37,919,155 shares of this class are outstanding. The shares to be sold were originally acquired from the issuer in a private placement on 07/03/2018 for cash.

HNGE has a shareholder filing a Form 144 notice to sell up to 677,508 Class A shares through Merrill Lynch on the NYSE, with an approximate aggregate market value of $33,136,916.28. The filing notes that there were 37,919,155 shares of this class outstanding when the notice was prepared and that the proposed sales may begin on 12/01/2025. The shares were originally acquired from the issuer in a private placement on 07/03/2018 and paid for in cash.

HNGE reported that a holder of its Class A stock has filed a notice of proposed sale under Rule 144. The holder plans to sell 826,216 Class A shares through Merrill Lynch on the NYSE, with an approximate sale date of 12/01/2025. The filing lists an aggregate market value for these shares of $40,410,224.56. These Class A shares were originally acquired from the issuer in a private placement on 07/03/2018 and paid for in cash. The notice also states that 37,919,155 shares of this class were outstanding, providing a baseline for the size of the proposed sale.

Hinge Health, Inc. reported an insider equity transaction by its President on 12/01/2025. The filing shows that 5,126 shares of Class A common stock were disposed of in a transaction coded "F" at a price of $48.91 per share. This type of code indicates shares were withheld or surrendered to cover taxes associated with the vesting of restricted stock units, rather than being sold on the open market.

After this tax-related share cancellation, the reporting officer beneficially owns 784,776 shares of Class A common stock directly. The issuer satisfied the related federal and state tax withholding obligations in exchange for the relinquished shares, leaving the executive with a substantial continuing equity stake in the company.

Hinge Health, Inc.'s Chief Financial Officer reported a routine share disposition related to tax withholding on equity compensation. On 12/01/2025, the reporting person disposed of 8,213 shares of Class A common stock at $48.91 per share in an exempt transaction. After this transaction, the officer beneficially owned 471,665 shares directly.

The company explains that the shares were withheld and cancelled by the issuer to cover federal and state tax obligations arising from the vesting of restricted stock units, as permitted under Section 16b-3(e). This reflects standard administrative handling of equity awards rather than an open-market sale.

HNGE shareholder(s) filed a Form 144 notice to sell Class A common stock. The filing covers a proposed sale of 21,757 Class A shares through Merrill Lynch, with an aggregate market value of 1,088,937.85. The shares relate to a private placement acquisition on 02/04/2020, paid for in cash.

The filing notes that 37,919,155 Class A shares were outstanding at the time of the notice. It also discloses recent sales by affiliated Bessemer Venture Partners funds in November 2025, including blocks of 373,955, 103,160, 351,045 and 96,840 Class A shares, with individual transaction gross proceeds between 4,674,466.8 and 14,976,898. The seller represents they are not aware of undisclosed material adverse information about HNGE.